

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70254 A1

(51) International Patent Classification⁷: A61K 38/17, A61P 3/04, 3/10, 5/48, C07K 14/705

(21) International Application Number: PCT/GB01/01211

(22) International Filing Date: 19 March 2001 (19.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0006864.3 21 March 2000 (21.03.2000) GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAIRNS, William, John [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). HOLDER, Julie, Caroline [GB/GB]; Glaxo-SmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). PATEL, Lisa [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(74) Agent: CONNELL, Anthony, Christopher; Corporate Intellectual Property, SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:
27 December 2001

(15) Information about Correction:
see PCT Gazette No. 52/2001 of 27 December 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/70254 A1

(54) Title: USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

(57) Abstract: The use of NOT1 or NOT1a polypeptides and polynucleotides in the design of protocols for the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia or liposarcoma, among others, and diagnostic assays for such conditions.

AN

USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

Field of the Invention

This invention relates to new uses for polynucleotides and polypeptides encoded by them, to their use in therapy and in identifying compounds which may be agonists which are potentially useful in therapy.

5

Summary of the Invention

In one aspect, the invention relates to new uses of the orphan nuclear receptor, NOT1 or its splice variant NOT1a polynucleotides and polypeptides. Such uses include the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, 10 hereinafter referred to as "the Diseases", amongst others. In another aspect the invention relates to methods for identifying compounds which activate NOT1 or NOT1a polypeptides, for example agonists, using NOT1 or NOT1a materials, and treating conditions associated with NOT1 or NOT1a imbalance with the identified agonist compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NOT1 or NOT1a 15 activity or levels.

Description of the Invention

In a first aspect, the present invention relates to the use of a compound selected from:

- (a) a NOT1 or NOT1a polypeptide;
- 20 (b) a compound which activates a NOT1 or NOT1a polypeptide; or
- (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,

for the manufacture of a medicament for treating:

- (i) obesity;
- (ii) insulin resistance;
- 25 (iii) type 2 diabetes;
- (iv) impaired glucose tolerance;
- (v) cachexia; or
- (vi) liposarcoma.

30 Such NOT1 polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

Further polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2. Further peptides include isolated polypeptides encoded by a polynucleotide comprising 5 the sequence contained in SEQ ID NO:1.

NOT1a polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include those comprising the amino acid of SEQ ID NO:4

10 Further NOT1a polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include the polypeptide of SEQ ID NO:4. Further peptides include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

15 The polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

20 The NOT1 and NOT1a polypeptides relating to the present invention also include variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic 25 residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

NOT1 and NOT1a polypeptides relating to the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides 30 produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to NOT1 or NOT1a polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID

NO:4, over the entire length of SEQ ID NO:2 or SEQ ID NO:4. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID

5 NO:1 or SEQ ID NO:3 encoding the polypeptides of SEQ ID NO:2 and SEQ ID NO:4 respectively.

Further polynucleotides relating to the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 95% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 or SEQ ID NO:4, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-
10 99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

Further polynucleotides include isolated polynucleotides comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO:1 or SEQ ID NO:3 over the entire length of SEQ ID NO:1 or SEQ ID NO:3 respectively. In this regard, polynucleotides which have at least 97%
15 identity are highly preferred, whilst those with at least 98-99% identiy are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3 as well as the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.

The invention also relates to polynucleotides which are complementary to all the above
20 described polynucleotides.

The nucleotide sequence of a human NOT1 cDNA is given in SEQ ID NO:1 (from Mages, H.W. et al. Mol. Endocrinol. 1994; 4(11): 1583-1591, EMBL: X75918). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 318 to 3115) encoding a polypeptide of 598 amino acids, the polypeptide of SEQ ID NO:2. The
25 nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The nucleotide sequence of the splice variant NOT1a is given in SEQ ID NO:3 (from Patent Application WO00/77202; SmithKline Beecham)
30 and is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 1 to 1368) encoding a polypeptide of 455 amino acids, the polypeptide of SEQ ID NO:4., representing a splice variant of NOT1. The nucleotide sequence encoding the polypeptide of SEQ ID NO:4 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:3 or it may be a

sequence other than the one contained in SEQ ID NO:3, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:4.

The gene encoding the NOT1 polypeptide of SEQ ID NO:2 has been localised to human chromosome 2q22-2q23..

5 Preferred polypeptides and polynucleotides are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one NOT1 or NOT1a activity, which may include antigenic activity.

NOT1 and NOT1a polynucleotides may be obtained, using standard cloning and screening 10 techniques, from a cDNA library derived from mRNA in cells of human brain (Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Such polynucleotides can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

15 When NOT1 or NOT1a polynucleotides are used for the recombinant production of NOT1 or NOT1a polypeptides, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or preprotein sequence, or other fusion peptide portions. For example, a marker sequence which 20 facilitates purification of the fused polypeptide can be encoded, for example a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

25 Recombinant NOT1 or NOT1a polypeptides may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from NOT1 or NOT1a DNA constructs.

For recombinant production, host cells can be genetically engineered to incorporate 30 expression systems or portions thereof for NOT1 or NOT1a polynucleotides. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate

transfection, DEAE-dextran mediated transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect 5 cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK and HEK 293.

The appropriate nucleotide sequence may be inserted into an expression vector by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (supra). Appropriate secretion signals may be 10 incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is 15 recovered.

NOT1 or NOT1a polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, 20 and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of 25 SEQ ID NO:1 or SEQ ID NO:3 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression or otherwise altered expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, 30 urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled NOT1 or NOT1a nucleotide

sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (ee, e.g., Myers *et al.*, *Science* (1985) 230:1242).

5 Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, *Proc Natl Acad Sci USA* (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising NOT1 or NOT1a nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known

10 and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, *Science*, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the NOT1 gene by the methods described. In addition, 15 such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased level of polypeptide or mRNA. Decreased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can 20 be used to determine levels of a NOT1 or NOT1a protein in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

(a) a NOT1 or NOT1a polynucleotide, preferably the nucleotide sequence of SEQ ID NO: 1 or 25 SEQ ID NO:3, or fragments thereof;

(b) a nucleotide sequence complementary to that of (a);

(c) a NOT1 or NOT1a polypeptide, preferably the polypeptide of SEQ ID NO:2 or SEQ ID NO:4, or a fragment thereof; or

(d) an antibody to a NOT1 or NOT1a polypeptide, preferably to the polypeptide of SEQ ID NO:2 30 or SEQ ID NO:4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, amongst others.

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides
5 in the prior art.

Antibodies generated against NOT1 or NOT1a polypeptides may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used.
10 Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbore *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.
15

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a NOT1 or NOT1a polypeptide, or a fragment thereof, and various portions 20 of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation 25 of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

In a further aspect, the present invention provides for a method of screening compounds to 30 identify those which stimulate the function of NOT1 or NOT1a polypeptides. In general, agonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the

polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by
5 means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Further, the screening methods may simply comprise the steps of mixing a
10 candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring NOT1 or NOT1a activity in the mixture, and comparing the NOT1 or NOT1a activity of the mixture to a standard.

NOT1 or NOT1a polynucleotides, polypeptides and antibodies to the polypeptide as hereinabove described may also be used to configure screening methods for detecting the effect
15 of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may enhance the production of polypeptide, for example agonists, from suitably manipulated cells or tissues.

20 The NOT1 or NOT1a polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated
25 with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists of NOT1 or NOT1a polypeptides which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

30 Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which enhance the production of such polypeptides, which comprises:

- (a) a NOT1 or NOT1a polypeptide;
- (b) a recombinant cell expressing a NOT1 or NOT1a polypeptide;

(c) a cell membrane expressing a NOT1 or NOT1a polypeptide; or

(d) antibody to a NOT1 or NOT1a polypeptide;

which NOT1 or NOT1a polypeptide is preferably that of SEQ ID NO:2 or SEQ ID NO:4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial
5 component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist of the NOT1 or NOT1a polypeptide, by:

- (a) determining in the first instance the three-dimensional structure of the NOT1 or NOT1a polypeptide;
- 10 (b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist;
- (c) synthesising candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and
- 15 (d) testing whether the candidate compounds are indeed agonists.

It will be further appreciated that this will normally be an iterative process.

- In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia, or liposarcoma, related to an under-expression of, NOT1 or NOT1a polypeptide activity.

20 For treating abnormal conditions related to an under-expression of NOT1 or NOT1a polypeptides and their activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of NOT1 or NOT1a by the relevant cells in the subject. For example, a NOT1 or NOT1a polynucleotide may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a NOT1 or NOT1a polypeptide such that the packaging 25 cell now produces infectious viral particles containing the NOT1 or NOT1a gene. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the NOT1 or NOT1a polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another 30

approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a NOT1 or NOT1a polypeptide, such as the soluble 5 form of a NOT1 or NOT1a polypeptide, agonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. 10 NOT1 or NOT1a polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be 15 used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a NOT1 or NOT1a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the 20 like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be 25 expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

NOT1 or NOT1a polypeptides used in treatment can also be generated endogenously in the 30 subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a NOT1 or NOT1a polynucleotide, such as a DNA or RNA, to encode a NOT1 or NOT1a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

5 "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

10 "Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

15 "Polynucleotide" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.

20 "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as

25 oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.

30 "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone,

the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching.

5 Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking,

10 cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for

15 instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis:

20 Post-translational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62).

 "Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a

25 polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many

30 regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that

is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.

5 In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*,

10 Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity

15 are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410

20 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

25 1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)
Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad. Sci. USA.* 89:10915-10919 (1992)

Gap Penalty: 12
Gap Length Penalty: 4

30 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the
5 default parameters for nucleic acid comparisons.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1 or SEQ ID NO:3, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide
10 deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of
15 nucleotides in SEQ ID NO:1 or SEQ ID NO:3 by the numerical percent of the respective percent identity(divided by 100) and subtracting that product from said total number of nucleotides in
- SEQ ID NO:1 or SEQ ID NO:3, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein n_n is the number of nucleotide alterations, x_n is the total number of nucleotides in SEQ
20 ID NO:1 or SEQ ID NO:3, and y is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%,etc., and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:4 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the
25 polynucleotide following such alterations.

Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2 or SEQ ID NO:4, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group
30 consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of

amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4 by the numerical percent of the respective percent identity(divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, or:

5

$$n_a \leq x_a - (x_a \cdot y),$$

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, and y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

10

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described. Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a 15 polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species.

15

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

20

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

25

Examples**Example 1 - Analysis of NOT1 and NOT1a expression in human tissues**

5

Generation of samples for TaqMan mRNA analysis: Human tissue or RNA was purchased (Biochain, San Leandro, CA; Invitrogen, Leek, The Netherlands; Clontech, Palo Alto, CA) or donated (Netherlands Brain Bank, Amsterdam, the Netherlands) and poly A+ RNA was prepared by the PolyATract method according to manufacturers instructions (Promega, USA). The poly 10 A+ RNA samples from 20 body tissues and 19 brain-regions from 4 individuals per tissue (two males/two females) were quantitated using OD260nm measurement or the RiboGreen fluorescent method (Molecular Probes, Oregon, USA) and 1ug of each RNA was reverse transcribed using random nonomeric and Superscript II reverse transcriptase according to manufacturers 15 instructions (Life Technologies). The cDNA prepared was diluted to produce up to 1,000 replicate 96-well plates using Biomek robotics (Beckman Coulter, High Wycombe, UK), so that each of the wells contained the cDNA produced from 1ng RNA for the appropriate tissue. The 96-well plates were stored at -80°C prior to use.

TaqMan PCR: This was performed following the procedure published by Sarau H.M. et al, 20 ("Identification, Molecular Cloning, Expression and Characterisation of a Cysteinyl Leukotriene Receptor", Molecular Pharmacology, 1999, 56, 657-663.) TaqMan quantitative PCR was conducted to measure either NOT-1 or NOT1a using replicate 96-well plates. A 20ul volume of a PCR master mix (containing 2.5ul TaqMan buffer, 6ul 25mM MgCl₂, 0.5ul of 10mM dATP, 0.5ul of 20mM dUTP, 0.5ul of 10mM dCTP, 0.5ul of 10mM dGTP, 0.25ul Uracil-N-glycosylase, 25 1ul of 10uM forward primer, 1ul of 10uM reverse primer, 0.5ul 5uM TaqMan probe, 0.125ul TaqGold [PE Biosystems], 6.625ul water) was added to each well using Biomek robotics (Beckman Coulter, High Wycombe, UK), and the plate capped using optical caps (PE Biosystems). The PCR reaction was carried out on an ABI7700 Sequence Detector (PE Biosystems) using the PCR parameters: 50°C for 2 minutes, 95°C for 10 minutes and 45 cycles 30 of 94°C for 15 seconds, 60°C for 1 minute, and the level of mRNA-derived cDNA in each sample was calculated from the TaqMan signal using plasmid/genomic DNA calibration standards included in each run. The level of genomic DNA contaminating the original RNA samples was shown to be negligible (<10 copies genomic DNA/ng RNA) by TaqMan measurement of genomic sequence for ten genes in replicate samples taken through the reverse transcription

procedure described with the omission of reverse transcriptase. Gene-specific reagents for NOT-1:

forward primer: 5'-CCGCCAGCAATAATTGACAA-3',

reverse primer: 5'-TTCCATTATCATTCCAGTTCCCTTG-3',

5 TaqMan probe: 5'-CACTTACCTTCTAAGACCTCCTCCAAGCA-3';
and for NOT1a:

forward primer: 5'-TCCTTCGATTAGCATACAGAATA-3',

reverse primer: 5'-CCCGTGTCTCTGTGACCAT-3',

TaqMan probe: 5'-TCTGCCTCTCCTGCATTGCTGCC-3'.

10

Results

The results are shown in Table 1. Analysis of expression of both NOT1 and NOT1a mRNA by TaqMan showed relatively widespread distribution. However, the expression levels found in adipose tissue were significantly higher than for those found in any other tissue. Levels 15 of expression are scored from +++++ to -, with +++++ representing the highest expression levels. +/- indicates weakly detectable expression.

Table 1

		NOT1	NOT1a
20	Brain	++	+
	Pituitary	+++	++
	Heart	+	+/-
	Lung	+	+/-
	Liver	+	+
25	Foetal Liver	+	+/-
	Kidney	+	+
	Skeletal Muscle	++	++
	Stomach	+	+
	Intestine	+	+
30	Spleen	+	+
	Lymphocytes	++	++
	Macrophage	-	-
	Adipose	+++++	+++++
	Pancreas	+	+
35	Prostate	++	+

Placenta	+	+
Cartilage	+	+
Bone	-	-
Bone Marrow	+/-	+/-

5

Example 2 - Analysis of NOT1 expression in 3T3 cells

Insulin and dexamethasone induced differentiation of 3T3-L1 cells is an established in vitro model for adipogenesis. Levels of NOT1 mRNA were quantified in this model. The 3T3-L1 fibroblast cell line was obtained from the American Type Culture Collection. Cells were 10 grown to confluence in Dulbeccos modified Eagles Medium containing 10% FCS. Differentiation was undertaken with in Dulbeccos modified Eagles Medium containing 10% FCS supplemented with 0.5mM isobutyl methyl xanthine, 0.25uM dexamethasone and insulin (5ug/ml) for 48 hours followed by Dulbeccos modified Eagles Medium containing 10% FCS supplemented with insulin (5ug/ml) for a further 48 hours. Cells were grown in Dulbeccos modified Eagles Medium 15 containing 10% FCS for the remainder of the culture period.

On each day of experimentation the cell media was removed by aspiration and the cell monolayer extracted with 1ml of Trizol. RNA was prepared according to the manufacturer's instructions. Quantification of mRNA transcripts was carried out using the Taqman 5' nuclease assay as previously described (Wang T & Brown MJ (1999) Anal. Biochem. 269 p198-201). 20 Total RNA was treated with DNaseI (Gibco BRL) and reverse transcribed using random hexamers (Stratagene) and Superscript II reverse transcriptase (Gibco BRL). Transcript cDNA levels were then measured using Taqman assay primers and fluorogenic probes as described in example 1. The results are shown in Table 2. In Table 2, T1 refers to day 1, T2 to day 2 etc. and the figures in the right hand column indicate relative levels of Not1 mRNA, the figure on day 1 25 being 100%.

Table 2

T1	100
T2	139
T3	57
T4	2.8
T5	3.7
T6	0.9
T7	3.9
T8	8.7
T9	0.6
T10	n.d.
T11	3.4
T12	8.5

The results show that NOT1 expression is downregulated upon differentiation of 3T3-L1 cells,
an established in vitro model for adipogenesis. This finding is consistent with NOT1 having a
5 function in maintaining the undifferentiated pre-adipocyte state.

Claims

1. The use of a compound selected from:
 - (a) a NOT1 or NOT1a polypeptide;
 - (b) a compound which activates a NOT1 or NOT1a polypeptide; or
 - (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,
for the manufacture of a medicament for treating:
 - (i) obesity;
 - (ii) insulin resistance;
 - (iii) type 2 diabetes;
 - (iv) impaired glucose tolerance;
 - (v) cachexia; or
 - (vi) liposarcoma.
- 15 2. The use according to claim 1 wherein the medicament is used to treat obesity.
3. The use according to claim 1 wherein the medicament is used in the treatment of insulin resistance.
- 20 4. The use according to claim 1 wherein the medicament comprises an isolated polypeptide which comprises a polypeptide having at least 95% identity to the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
- 25 5. The use according to claim 4 wherein the isolated polypeptide is the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
6. The use according to claim 1 wherein the medicament comprises a compound which activates a NOT or NOT1a polypeptide.
- 30 7. The use according to claim 1 wherein the medicament comprises a polynucleotide encoding a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
- 35 8. The use according to claim 7 wherein the polynucleotide comprises a polynucleotide having at least 95% identity with the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.
9. The use according to claim 7 or 8 wherein the polynucleotide has the polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3.

SEQUENCE LISTING

<110> SmithKline Beecham plc

<120> New Use

<130> P32537.

<160> 4

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 3427

<212> DNA

<213> Homo sapiens

<400> 1

gctcgccac ggctccgcgg tccctttgc ctgtccagcc ggccgcctgt ccctgtccc	60
tccctccgtg agtgtccggg ttcccttcgc ccagctctcc cacccttacc cgaccccgcc	120
gccccggcgc ccagagggaa ctgcacttcg gcagagtta atgaatgaag agagacgcgg	180
agaactccta aggaggagat tggacaggct ggactcccca ttgctttct aaaaatcttg	240
gaaactttgt ctttcattga attacgacac tgtccacctt taatttcctc gaaaacgcct	300
gttaactcgcc tgaagccatg ctttgcgttc aggccgcgtt tggtccctcg cctcaaggag	360
ccagccccgc ttctcagagc tacagttacc actcttcggg agaatacagc tccgatttct	420
taactccaga gtttgtcaag tttagcatgg acctcaccaa cactgaaatc actgccacca	480
cttctctccc cagtttcagt acctttatgg acaactacag cacaggctac gacgtcaagc	540
caccttgctt gtaccaaatg cccctgtcccg gacagcagtc ctccatthaag gtagaagaca	600
ttcagatgca caactaccag caacacagcc acctgcccccc ccagtctgag gagatgatgc	660
cgcactccgg gtcgggtttac tacaaggcct cctcgcccccc gacgcccacc accccgggct	720
tccagggtgca gcacagcccc atgtgggacg accccggatc tctccacaac ttccaccaga	780
actacgtggc cactacgcac atgatcgagc agaggaaaac gccagtcctcc cgcctctccc	840
tcttcctttaa taaatcg cccctggca ccccggtgtc tagttgccag atgcgtttcg	900
acggccccct gcacgtcccc atgaacccgg agccccccgg cagccaccac gtgggtggacg	960
ggcagacccctt cgctgtgccc aaccccatc gcaagccccgc gtccatggc ttcccgcc	1020
tgcagatcggtt ccacgcgtct cagctgtctc acacgcggat gcctcaccg ccgtcgccgg	1080
gtcccccttc caacgagggg ctgtgcgtc tgggtgggaa caacgcggcc tgccaacact	1140
acggcggtcgac cacctgtgag ggctgaaatg gcttctttaa ggcgcacagtg caaaaaaaatg	1200

caaaatacgt	gtgttttagca	aataaaaaact	gcccaagtggaa	caagcgtcgcc	cggaaatcgct	1260
gtcagtactg	ccgatttcag	aagtgcctgg	ctgttgggat	ggtcaaagaa	gtggttcgca	1320
cagacagtt	aaaaggccccg	agaggtcggt	tgcgcctcgaa	accgaagagc	ccacaggagc	1380
cctctccccc	ttcgccccccg	gtgagtcgt	tcagtgccct	cgtcaggggcc	catgtcgact	1440
ccaacccggc	tatgaccagc	ctggacttatt	ccaggttcca	ggcgaaccct	gactatcaaa	1500
tgagtggaga	tgacacccag	cataatccgc	aattctatga	tctcctgact	ggctccatgg	1560
agatcatccg	gggctgggca	gagaagatcc	ctgcttcgc	agacctgccc	aaagccgacc	1620
aagacctgct	ttttgaatca	gctttcttag	aactgtttgt	ctttcgatta	gcatacaggt	1680
ccaaacccagt	ggagggttaaa	ctcatcttt	gcaatggggt	gtcttgcac	aggttgcata	1740
gcgttctgtgg	ctttggggaa	tggattgatt	ccattgttga	attctctcc	aacttgcaga	1800
atatgaacat	cgacatttct	gccttcctc	gcattgctgc	cctggctatg	gtcacagaga	1860
gacacgggct	caaggaaccc	aagagagtgg	aagaactgca	aaacaagatt	gtaaattgtc	1920
tcaaagacca	cgtgacttcc	aacaatgggg	ggttgaaccg	cccccaattat	ttgtccaaac	1980
tgttggggaa	gctcccagaa	cttcgtaccc	tttgcacacaca	ggggctacag	cgcaitttct	2040
acctgaaatt	ggaagacttg	gtgccaccgc	cagcaataat	tgacaaaactt	ttcctggaca	2100
cttaccttt	ctaagacctc	ctcccaagca	cttcaaagga	actggaatga	taatggaaac	2160
tgtcaagagg	gggcaagtca	catggcaga	gatagccgtg	tgagcagtct	cagctcaagc	2220
tgccccccat	ttctgttaacc	ctcctagccc	ccttgatccc	taaagaaaaac	aaacaaacaa	2280
acaaaaactg	ttgctatttc	ctaaccgtca	ggcagaacct	gaaaggcat	tttggctccg	2340
gggcattcctg	gatttagaaac	atggactaca	cacaatacag	tggataaac	tttttattct	2400
cagtttaaaa	atcagtttgc	tgttcagaag	aaagattgct	ataaggata	atggaaatg	2460
tttggccatg	cttgggttgt	gcagttcaga	caaatgtaac	acacacacac	atacacacac	2520
acacacacac	agagacacat	cttaaggggaa	cccacaagta	ttgccttta	acaagacttc	2580
aaagtttct	gctgtaaaga	aagctgtat	atatagtaaa	actaaatgtt	gcgtgggtgg	2640
catgagttga	agaaggcaaa	ggcttgcata	tttacccaaat	gcagtttggc	tttttaattt	2700
attttgc	tatattgaa	taaatattac	aaattctaaa	agataagtgt	gtttgcaaaa	2760
aaaaagaaaa	taaatacata	aaaaaggac	aagcatgttg	attctaggtt	aaaaatgtta	2820
taggcacttg	ctacttcagt	aatgtctata	ttatataat	agtatttcag	acactatgt	2880
gtctgttga	ttttataaaag	attggtagtt	atctgagctt	aaacattttc	tcaattgtaa	2940
aataggtggg	cacaagtatt	acacatcaga	aaatcctgac	aaaaggacac	catagtgtt	3000
gtaacaccgt	ccaacattcc	ttgtttgtaa	gtgttgtatg	taccgttgc	gttgataaaa	3060
agaaaagttt	tatcttgatt	attttgcgt	ctaaagctaa	acaaaacttg	catgcagcag	3120
cttttgactg	tttccagagt	gcttataata	tacataactc	cctggaaata	actgagcact	3180
ttgaattttt	tttatgtcta	aaattgtcag	ttaatttatt	atttgttttgc	agtaagaatt	3240
ttaatattgc	catattctgt	agtattttc	tttgcataatt	tctagttatgg	cacatgat	3300
gagtcactgc	ctttttttct	atgggtgtatg	acagtttagag	atgctgat	tttttctgat	3360
aaattcttcc	tttgagaaag	acaattttaa	tgtttacaac	aataaaccat	gtaaatgaaa	3420
aaaaaaaa						3427

<211> 598

<212> PRT

<213> Homo sapiens

<400> 2

Met	Pro	Cys	Val	Gln	Ala	Gln	Tyr	Gly	Ser	Ser	Pro	Gln	Gly	Ala	Ser
1				5					10					15	
Pro	Ala	Ser	Gln	Ser	Tyr	Ser	Tyr	His	Ser	Ser	Gly	Glu	Tyr	Ser	Ser
					20				25					30	
Asp	Phe	Leu	Thr	Pro	Glu	Phe	Val	Lys	Phe	Ser	Met	Asp	Leu	Thr	Asn
					35				40					45	
Thr	Glu	Ile	Thr	Ala	Thr	Thr	Ser	Leu	Pro	Ser	Phe	Ser	Thr	Phe	Met
					50			55					60		
Asp	Asn	Tyr	Ser	Thr	Gly	Tyr	Asp	Val	Lys	Pro	Pro	Cys	Leu	Tyr	Gln
					65			70					75		80
Met	Pro	Leu	Ser	Gly	Gln	Gln	Ser	Ser	Ile	Lys	Val	Glu	Asp	Ile	Gln
					85				90					95	
Met	His	Asn	Tyr	Gln	Gln	His	Ser	His	Leu	Pro	Pro	Gln	Ser	Glu	Glu
					100				105					110	
Met	Met	Pro	His	Ser	Gly	Ser	Val	Tyr	Tyr	Lys	Pro	Ser	Ser	Pro	Pro
					115			120					125		
Thr	Pro	Thr	Thr	Pro	Gly	Phe	Gln	Val	Gln	His	Ser	Pro	Met	Trp	Asp
					130			135					140		
Asp	Pro	Gly	Ser	Leu	His	Asn	Phe	His	Gln	Asn	Tyr	Val	Ala	Thr	Thr
					145			150					155		160
His	Met	Ile	Glu	Gln	Arg	Lys	Thr	Pro	Val	Ser	Arg	Leu	Ser	Leu	Phe
					165				170					175	
Ser	Phe	Lys	Gln	Ser	Pro	Pro	Gly	Thr	Pro	Val	Ser	Ser	Cys	Gln	Met
					180				185					190	
Arg	Phe	Asp	Gly	Pro	Leu	His	Val	Pro	Met	Asn	Pro	Glu	Pro	Ala	Gly
					195			200					205		
Ser	His	His	Val	Val	Asp	Gly	Gln	Thr	Phe	Ala	Val	Pro	Asn	Pro	Ile
					210			215					220		
Arg	Lys	Pro	Ala	Ser	Met	Gly	Phe	Pro	Gly	Leu	Gln	Ile	Gly	His	Ala
					225			230					235		240
Ser	Gln	Leu	Leu	Asp	Thr	Gln	Val	Pro	Ser	Pro	Pro	Ser	Arg	Gly	Ser
					245				250					255	
Pro	Ser	Asn	Glu	Gly	Leu	Cys	Ala	Val	Cys	Gly	Asp	Asn	Ala	Ala	Cys
					260				265					270	
Gln	His	Tyr	Gly	Val	Arg	Thr	Cys	Glu	Gly	Cys	Lys	Gly	Phe	Phe	Lys

275	280	285
Arg Thr Val Gln Lys Asn Ala Lys Tyr Val Cys Leu Ala Asn Lys Asn		
290	295	300
Cys Pro Val Asp Lys Arg Arg Arg Asn Arg Cys Gln Tyr Cys Arg Phe		
305	310	315
Gln Lys Cys Leu Ala Val Gly Met Val Lys Glu Val Val Arg Thr Asp		
325	330	335
Ser Leu Lys Gly Arg Arg Gly Arg Leu Pro Ser Lys Pro Lys Ser Pro		
340	345	350
Gln Glu Pro Ser Pro Pro Ser Pro Pro Val Ser Leu Ile Ser Ala Leu		
355	360	365
Val Arg Ala His Val Asp Ser Asn Pro Ala Met Thr Ser Leu Asp Tyr		
370	375	380
Ser Arg Phe Gln Ala Asn Pro Asp Tyr Gln Met Ser Gly Asp Asp Thr		
385	390	395
Gln His Ile Gln Gln Phe Tyr Asp Leu Leu Thr Gly Ser Met Glu Ile		
405	410	415
Ile Arg Gly Trp Ala Glu Lys Ile Pro Gly Phe Ala Asp Leu Pro Lys		
420	425	430
Ala Asp Gln Asp Leu Leu Phe Glu Ser Ala Phe Leu Glu Leu Phe Val		
435	440	445
Leu Arg Leu Ala Tyr Arg Ser Asn Pro Val Glu Gly Lys Leu Ile Phe		
450	455	460
Cys Asn Gly Val Val Leu His Arg Leu Gln Cys Val Arg Gly Phe Gly		
465	470	475
Glu Trp Ile Asp Ser Ile Val Glu Phe Ser Ser Asn Leu Gln Asn Met		
485	490	495
Asn Ile Asp Ile Ser Ala Phe Ser Cys Ile Ala Ala Leu Ala Met Val		
500	505	510
Thr Glu Arg His Gly Leu Lys Glu Pro Lys Arg Val Glu Glu Leu Gln		
515	520	525
Asn Lys Ile Val Asn Cys Leu Lys Asp His Val Thr Phe Asn Asn Gly		
530	535	540
Gly Leu Asn Arg Pro Asn Tyr Leu Ser Lys Leu Leu Gly Lys Leu Pro		
545	550	555
Glu Leu Arg Thr Leu Cys Thr Gln Gly Leu Gln Arg Ile Phe Tyr Leu		
565	570	575
Lys Leu Glu Asp Leu Val Pro Pro Ala Ile Ile Asp Lys Leu Phe		
580	585	590
Leu Asp Thr Leu Pro Phe		

595

<210> 3

<211> 1676

<212> DNA

<213> Homo sapiens

<400> 3

atgccttgc ttcaggcgca	gtatgggtcc tcgcctcaag gagccagccc cgcttctcag	60
agctacagtt accactttc	gggagaatac agctccgatt tcttaactcc agagtttgtc	120
aagttagca tggacctcac	caacactgaa atcactgcca ccacttctct cccccagcttc	180
agtacccctta tggacaacta	cagcacaggc tacgacgtca agccaccttg cttgtaccaa	240
atgcccctgt ccggacagca	gtcctccatt aaggtagaag acattcagat gcacaactac	300
cagcaacaca gccacctgcc	cccccaagtct gaggagatga tgccgcactc cgggtcggtt	360
tactacaagc ctcctcgcc	cccgacgccc accaccccg gcttccaggt gcagcacagc	420
cccatgtggg acgaccggg	atctctccac aacttccacc agaactacgt ggccactacg	480
cacatgatcg agcagaggaa	aacgcctgc tcccgcctct ccctttctc cttaagcaa	540
tcgccccctg gcaccccggt	gtcttagttgc cagatgcgt tcgacgggccc cctgcacgtc	600
cccatgaacc cggagccgc	cgccgaccac cacgtgggg acgggcagac cttcgctgtg	660
cccaacccca ttgcgaagcc	cgcgcccatg ggcttcccg ggctgcagat cggccacgcg	720
tctcagctgc tcgacacgc	ggtgcctca ccgcgcgtgc ggggctccccc ctccaacgcg	780
gggcgtgtcg ctgtgtgtgg	ggacaacgcg gcctgcacac actacggcgt ggcacacgt	840
gagggtgtca aaggcttctt	taagcgcaca gtgcaaaaaaa atgcaaaaata cgtgtgtta	900
gcaaaaaaaa actgcccagt	ggacaaggct cgccgaaatc gctgtcagta ctgcgcattt	960
cagaagtgcc tggctgttgg	gatggtcaaa gaagtgggtc gcacagacag tttaaaaggc	1020
cggagaggtc gtttgcctc	gaaaccgaag agcccacagg agccctctcc cccttcgc	1080
ccgggtgagtc tgatcagtgc	cctcgtcagg gccatgtcg actccaaaccc ggctatgacc	1140
agcctggact attccaggtt	ccaggcgaac cctgactatc aaatgagtgg agatgacacc	1200
cagcatatcc agcaattcta	tgatctctgc actggctcca tggagatcat ccggggctgg	1260
gcagagaaga tccctggctt	cgcagacctg cccaaagccg accaagaccc gctttttgaa	1320
ttagactgtt tgccttcga	tttagcataca gaatatgaac atcgacattt	1380
ctgccttctc ctgcattgtct	gcccggctca tggcacaga gagacacggg ctcaaggaac	1440
ccaagagagt ggaagaactg	caaaaacaaga ttgtaaattt tctcaaagac cacgtgactt	1500
tcaacaatgg ggggttgaac	cgccccaatt atttgcacaa actgttgggg aagctcccag	1560
aactcgtac ctttgcaca	caggggctac agcgcatatcc ctacacgtaaa ttgaaagact	1620
tggtgcacc	gccagcaata attgacaac tttcttgcga cactttaccc ttctaa	1676

<210> 4

<211> 455

<212> PRT

<213> Homo sapiens

<400> 4

Met Pro Cys Val Gln Ala Gln Tyr Gly Ser Ser Pro Gln Gly Ala Ser
 1 5 10 15
 Pro Ala Ser Gln Ser Tyr Ser Tyr His Ser Ser Gly Glu Tyr Ser Ser
 20 25 30
 Asp Phe Leu Thr Pro Glu Phe Val Lys Phe Ser Met Asp Leu Thr Asn
 35 40 45
 Thr Glu Ile Thr Ala Thr Thr Ser Leu Pro Ser Phe Ser Thr Phe Met
 50 55 60
 Asp Asn Tyr Ser Thr Gly Tyr Asp Val Lys Pro Pro Cys Leu Tyr Gln
 65 70 75 80
 Met Pro Leu Ser Gly Gln Gln Ser Ser Ile Lys Val Glu Asp Ile Gln
 85 90 95
 Met His Asn Tyr Gln Gln His Ser His Leu Pro Pro Gln Ser Glu Glu
 100 105 110
 Met Met Pro His Ser Gly Ser Val Tyr Tyr Lys Pro Ser Ser Pro Pro
 115 120 125
 Thr Pro Thr Thr Pro Gly Phe Gln Val Gln His Ser Pro Met Trp Asp
 130 135 140
 Asp Pro Gly Ser Leu His Asn Phe His Gln Asn Tyr Val Ala Thr Thr
 145 150 155 160
 His Met Ile Glu Gln Arg Lys Thr Pro Val Ser Arg Leu Ser Leu Phe
 165 170 175
 Ser Phe Lys Gln Ser Pro Pro Gly Thr Pro Val Ser Ser Cys Gln Met
 180 185 190
 Arg Phe Asp Gly Pro Leu His Val Pro Met Asn Pro Glu Pro Ala Gly
 195 200 205
 Ser His His Val Val Asp Gly Gln Thr Phe Ala Val Pro Asn Pro Ile
 210 215 220
 Arg Lys Pro Ala Ser Met Gly Phe Pro Gly Leu Gln Ile Gly His Ala
 225 230 235 240
 Ser Gln Leu Leu Asp Thr Gln Val Pro Ser Pro Pro Ser Arg Gly Ser
 245 250 255
 Pro Ser Asn Glu Gly Leu Cys Ala Val Cys Gly Asp Asn Ala Ala Cys
 260 265 270
 Gln His Tyr Gly Val Arg Thr Cys Glu Gly Cys Lys Gly Phe Phe Lys
 275 280 285
 Arg Thr Val Gln Lys Asn Ala Lys Tyr Val Cys Leu Ala Asn Lys Asn

290	295	300
Cys Pro Val Asp Lys Arg Arg Arg Asn Arg Cys Gln Tyr Cys Arg Phe		
305	310	315
Gln Lys Cys Leu Ala Val Gly Met Val Lys Glu Val Val Arg Thr Asp		
325	330	335
Ser Leu Lys Gly Arg Arg Gly Arg Leu Pro Ser Lys Pro Lys Ser Pro		
340	345	350
Gln Glu Pro Ser Pro Pro Ser Pro Pro Val Ser Leu Ile Ser Ala Leu		
355	360	365
Val Arg Ala His Val Asp Ser Asn Pro Ala Met Thr Ser Leu Asp Tyr		
370	375	380
Ser Arg Phe Gln Ala Asn Pro Asp Tyr Gln Met Ser Gly Asp Asp Thr		
385	390	395
Gln His Ile Gln Gln Phe Tyr Asp Leu Leu Thr Gly Ser Met Glu Ile		
405	410	415
Ile Arg Gly Trp Ala Glu Lys Ile Pro Gly Phe Ala Asp Leu Pro Lys		
420	425	430
Ala Asp Gln Asp Leu Leu Phe Glu Ser Ala Phe Leu Glu Leu Phe Val		
435	440	445
Leu Arg Leu Ala Tyr Arg Ile		
450	455	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 01/01211

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/17 A61P3/04 A61P3/10 A61P5/48 C07K14/705																	
According to International Patent Classification (IPC) or to both national classification and IPC																	
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A61P C07K																	
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																	
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, EMBASE																	
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; padding: 2px;">Category</th> <th style="text-align: left; padding: 2px;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="text-align: left; padding: 2px;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">A</td> <td style="padding: 2px;">WO 94 04675 A (MAGES HANS WERNER ;KROCZEK RICHARD (DE)) 3 March 1994 (1994-03-03)</td> <td style="padding: 2px;"></td> </tr> <tr> <td style="padding: 2px;">A</td> <td style="padding: 2px;"> SALIN-NORDSTROM T ET AL: "FUNCTION OF HUMAN NOT (NRN1/NR4A2) SPLICE VARIANTS IN DEVELOPMENT AND PATHOLOGIES" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/02, 1999, page 1754 XP000949970 ISSN: 0190-5295 ----- </td> <td style="padding: 2px;"></td> </tr> <tr> <td></td> <td style="text-align: center; padding: 2px;">-/--</td> <td style="padding: 2px;"></td> </tr> </tbody> </table>						Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	A	WO 94 04675 A (MAGES HANS WERNER ;KROCZEK RICHARD (DE)) 3 March 1994 (1994-03-03)		A	SALIN-NORDSTROM T ET AL: "FUNCTION OF HUMAN NOT (NRN1/NR4A2) SPLICE VARIANTS IN DEVELOPMENT AND PATHOLOGIES" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/02, 1999, page 1754 XP000949970 ISSN: 0190-5295 -----			-/--	
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.															
A	WO 94 04675 A (MAGES HANS WERNER ;KROCZEK RICHARD (DE)) 3 March 1994 (1994-03-03)																
A	SALIN-NORDSTROM T ET AL: "FUNCTION OF HUMAN NOT (NRN1/NR4A2) SPLICE VARIANTS IN DEVELOPMENT AND PATHOLOGIES" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/02, 1999, page 1754 XP000949970 ISSN: 0190-5295 -----																
	-/--																
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.			<input checked="" type="checkbox"/> Patent family members are listed in annex.														
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority (claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed																	
T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *g* document member of the same patent family																	
Date of the actual completion of the international search		Date of mailing of the international search report															
11 July 2001		27/07/2001															
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3016			Authorized officer Blanco Urquiza, B														

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 01/01211

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MARUYAMA K ET AL: "THE NGFI-B SUBFAMILY OF THE NUCLEAR RECEPTOR SUPERFAMILY (REVIEW)" INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,,GR, vol. 12, no. 6, 23 March 1998 (1998-03-23), pages 1237-1243, XP000946431 ISSN: 1019-6439	
A	ISHIHARA NORIKO ET AL: "Signal transduction pathways leading to the NOR-1 gene induction in MCF-7 breast cancer cells." FASEB JOURNAL, vol. 11, no. 9, 1997, page A1047 XP002171751 17th International Congress of Biochemistry and Molecular Biology in conjunction with the Annual Meeting of the American Society for Biochemistry and Molecular Biology; San Francisco, California, USA; August 24-29, 1997 ISSN: 0892-6638	
A	MAMOUNAS M ET AL: "ANALYSIS OF THE GENES INVOLVED IN THE INSULIN TRANSMEMBRANE MITOGENIC SIGNAL IN CHINESE HAMSTER OVARY CELLS CHO-K1 UTILIZING INSULIN-INDEPENDENT MUTANTS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 88, no. 9, 1991, pages 3530-3534, XP002171752 1991 ISSN: 0027-8424	
A	WO 98 26063 A (MAIRA MARIO ;DROUIN JACQUES (CA); MONTREAL INST RECH CLINIQUES (CA) 18 June 1998 (1998-06-18)	
P,A	WO 00 77202 A (SMITHKLINE BEECHAM PLC) 21 December 2000 (2000-12-21) cited in the application	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 6

Claims 1 (partially) and 6 refer to the use of an agonist of the polypeptides without giving a true technical characterization. Moreover no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/01211

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9404675 A	03-03-1994	AU	4950393 A	15-03-1994
WO 9826063 A	18-06-1998	CA	2192754 A	12-06-1998
		AU	5470598 A	03-07-1998
WO 0077202 A	21-12-2000		NONE	

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70254 A1

(51) International Patent Classification⁷: A61K 38/17, A61P 3/04, 3/10, 5/48, C07K 14/705

(74) Agent: CONNELL, Anthony, Christopher; Corporate Intellectual Property, SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(21) International Application Number: PCT/GB01/01211

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 19 March 2001 (19.03.2001)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0006864.3 21 March 2000 (21.03.2000) GB

(71) Applicant (*for all designated States except US*):
SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CAIRNS, William, John [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). HOLDER, Julie, Caroline [GB/GB]; Glaxo-SmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). PATEL, Lisa [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A1
WO 01/70254

(54) Title: USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

(57) Abstract: The use of NOT1 or NOT1a polypeptides and polynucleotides in the design of protocols for the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia or liposarcoma, among others, and diagnostic assays for such conditions.

USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

Field of the Invention

This invention relates to new uses for polynucleotides and polypeptides encoded by them, to their use in therapy and in identifying compounds which may be agonists which are potentially useful in therapy.

5

Summary of the Invention

In one aspect, the invention relates to new uses of the orphan nuclear receptor, NOT1 or its splice variant NOT1a polynucleotides and polypeptides. Such uses include the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, 10 hereinafter referred to as "the Diseases", amongst others. In another aspect the invention relates to methods for identifying compounds which activate NOT1 or NOT1a polypeptides, for example agonists, using NOT1 or NOT1a materials, and treating conditions associated with NOT1 or NOT1a imbalance with the identified agonist compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NOT1 or NOT1a 15 activity or levels.

Description of the Invention

In a first aspect, the present invention relates to the use of a compound selected from:

- (a) a NOT1 or NOT1a polypeptide;
- 20 (b) a compound which activates a NOT1 or NOT1a polypeptide; or
- (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,

for the manufacture of a medicament for treating:

- (i) obesity;
- (ii) insulin resistance;
- 25 (iii) type 2 diabetes;
- (iv) impaired glucose tolerance;
- (v) cachexia; or
- (vi) liposarcoma.

30 Such NOT1 polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

Further polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2. Further peptides include isolated polypeptides encoded by a polynucleotide comprising 5 the sequence contained in SEQ ID NO:1.

NOT1a polypeptides include isolated polypeptides comprising an amino acid sequence which has at least 95% identity, preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include those comprising the amino acid of SEQ ID NO:4

10 Further NOT1a polypeptides include isolated polypeptides in which the amino acid sequence has at least 95% identity, preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4. Such polypeptides include the polypeptide of SEQ ID NO:4. Further peptides include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

15 The polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

20 The NOT1 and NOT1a polypeptides relating to the present invention also include variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic 25 residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

NOT1 and NOT1a polypeptides relating to the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides 30 produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to NOT1 or NOT1a polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID

NO:4, over the entire length of SEQ ID NO:2 or SEQ ID NO:4. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID

5 NO:1 or SEQ ID NO:3 encoding the polypeptides of SEQ ID NO:2 and SEQ ID NO:4 respectively.

Further polynucleotides relating to the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 95% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 or SEQ ID NO:4, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

10 Further polynucleotides include isolated polynucleotides comprising a nucleotide sequence which has at least 95% identity to SEQ ID NO:1 or SEQ ID NO:3 over the entire length of SEQ ID NO:1 or SEQ ID NO:3 respectively. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3 as well as the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.

15 The invention also relates to polynucleotides which are complementary to all the above described polynucleotides.

The nucleotide sequence of a human NOT1 cDNA is given in SEQ ID NO:1 (from Mages, H.W. et al. Mol. Endocrinol. 1994; 4(11): 1583-1591, EMBL: X75918). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 318 to 3115) encoding a polypeptide of 598 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The nucleotide sequence of the splice variant NOT1a is given in SEQ ID NO:3 (from Patent Application WO00/77202; SmithKline Beecham) and is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 1 to 1368) encoding a polypeptide of 455 amino acids, the polypeptide of SEQ ID NO:4., representing a splice variant of NOT1. The nucleotide sequence encoding the polypeptide of SEQ ID NO:4 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:3 or it may be a

sequence other than the one contained in SEQ ID NO:3, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:4.

The gene encoding the NOT1 polypeptide of SEQ ID NO:2 has been localised to human chromosome 2q22-2q23..

5 Preferred polypeptides and polynucleotides are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one NOT1 or NOT1a activity, which may include antigenic activity.

10 NOT1 and NOT1a polynucleotides may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human brain (Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Such polynucleotides can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

15 When NOT1 or NOT1a polynucleotides are used for the recombinant production of NOT1 or NOT1a polypeptides, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or preprotein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded, for example a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

20 25 Recombinant NOT1 or NOT1a polypeptides may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from NOT1 or NOT1a DNA constructs.

For recombinant production, host cells can be genetically engineered to incorporate 30 expression systems or portions thereof for NOT1 or NOT1a polynucleotides. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate

transfection, DEAE-dextran mediated transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect 5 cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK and HEK 293.

The appropriate nucleotide sequence may be inserted into an expression vector by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., Molecular Cloning, A Laboratory Manual (supra). Appropriate secretion signals may be 10 incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is 15 recovered.

NOT1 or NOT1a polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, 20 and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of 25 SEQ ID NO:1 or SEQ ID NO:3 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression or otherwise altered expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, 30 urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled NOT1 or NOT1a nucleotide

sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (ee, e.g., Myers *et al.*, *Science* (1985) 230:1242).

5 Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, *Proc Natl Acad Sci USA* (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising NOT1 or NOT1a nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known

10 and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, *Science*, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the NOT1 gene by the methods described. In addition, 15 such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased level of polypeptide or mRNA. Decreased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can 20 be used to determine levels of a NOT1 or NOT1a protein in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

(a) a NOT1 or NOT1a polynucleotide, preferably the nucleotide sequence of SEQ ID NO: 1 or 25 SEQ ID NO:3, or fragments thereof;

(b) a nucleotide sequence complementary to that of (a);

(c) a NOT1 or NOT1a polypeptide, preferably the polypeptide of SEQ ID NO:2 or SEQ ID NO:4, or a fragment thereof; or

(d) an antibody to a NOT1 or NOT1a polypeptide, preferably to the polypeptide of SEQ ID NO:2 30 or SEQ ID NO:4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia and liposarcoma, amongst others.

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides

5 in the prior art.

Antibodies generated against NOT1 or NOT1a polypeptides may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used.

10 Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

15 Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

20 In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a NOT1 or NOT1a polypeptide, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation 25 of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

30 In a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate the function of NOT1 or NOT1a polypeptides. In general, agonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the

polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by 5 means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Further, the screening methods may simply comprise the steps of mixing a 10 candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring NOT1 or NOT1a activity in the mixture, and comparing the NOT1 or NOT1a activity of the mixture to a standard.

NOT1 or NOT1a polynucleotides, polypeptides and antibodies to the polypeptide as hereinabove described may also be used to configure screening methods for detecting the effect 15 of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may enhance the production of polypeptide, for example agonists, from suitably manipulated cells or tissues.

20 The NOT1 or NOT1a polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated 25 with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists of NOT1 or NOT1a polypeptides which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

30 Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which enhance the production of such polypeptides, which comprises:

- (a) a NOT1 or NOT1a polypeptide;
- (b) a recombinant cell expressing a NOT1 or NOT1a polypeptide;

- (c) a cell membrane expressing a NOT1 or NOT1a polypeptide; or
- (d) antibody to a NOT1 or NOT1a polypeptide;

which NOT1 or NOT1a polypeptide is preferably that of SEQ ID NO:2 or SEQ ID NO:4.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial
5 component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist of the NOT1 or NOT1a polypeptide, by:

- (a) determining in the first instance the three-dimensional structure of the NOT1 or NOT1a polypeptide;
- 10 (b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist;
- (c) synthesizing candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and
- 15 (d) testing whether the candidate compounds are indeed agonists.

It will be further appreciated that this will normally be an iterative process.

In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia, or liposarcoma, related to an under-expression of, NOT1 or NOT1a polypeptide activity.

20 For treating abnormal conditions related to an under-expression of NOT1 or NOT1a polypeptides and their activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene
25 therapy may be employed to effect the endogenous production of NOT1 or NOT1a by the relevant cells in the subject. For example, a NOT1 or NOT1a polynucleotide may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a NOT1 or NOT1a polypeptide such that the packaging
30 cell now produces infectious viral particles containing the NOT1 or NOT1a gene. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the NOT1 or NOT1a polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another

approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a NOT1 or NOT1a polypeptide, such as the soluble form of a NOT1 or NOT1a polypeptide, agonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

NOT1 or NOT1a polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a NOT1 or NOT1a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

NOT1 or NOT1a polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a NOT1 or NOT1a polynucleotide, such as a DNA or RNA, to encode a NOT1 or NOT1a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

“Antibodies” as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an 5 Fab or other immunoglobulin expression library.

“Isolated” means altered “by the hand of man” from the natural state. If an “isolated” composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the 10 coexisting materials of its natural state is “isolated”, as the term is employed herein.

“Polynucleotide” generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- 15 and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term “polynucleotide” also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. 20 “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. “Polynucleotide” also embraces relatively short polynucleotides, often referred to as 25 oligonucleotides.

“Polypeptide” refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.

“Polypeptide” refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain 30 amino acids other than the 20 gene-encoded amino acids. “Polypeptides” include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone,

the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching.

5 Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking,

10 cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for

15 instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis:

20 Post-translational Modifications and Aging", Ann NY Acad Sci (1992) 663:48-62).

 "Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a

25 polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many

30 regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that

is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.

5 In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*,
10 Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity
15 are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410
20 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

25 1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)
Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad. Sci. USA.* 89:10915-10919 (1992)
Gap Penalty: 12
Gap Length Penalty: 4
30 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the
5 default parameters for nucleic acid comparisons.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1 or SEQ ID NO:3, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide
10 deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of
15 nucleotides in SEQ ID NO:1 or SEQ ID NO:3 by the numerical percent of the respective percent identity(divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:1 or SEQ ID NO:3, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein n_n is the number of nucleotide alterations, x_n is the total number of nucleotides in SEQ
20 ID NO:1 or SEQ ID NO:3, and y is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%,etc., and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 or SEQ ID NO:4 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the
25 polynucleotide following such alterations.

Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2 or SEQ ID NO:4, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group
30 consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of

amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4 by the numerical percent of the respective percent identity(divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, or:

5

$$n_a \leq x_a - (x_a \bullet y),$$

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2 or SEQ ID NO:4, and y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

10

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described. Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a 15 polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species.

20

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

25

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

Examples

Example 1 - Analysis of NOT1 and NOT1a expression in human tissues

5

Generation of samples for TaqMan mRNA analysis: Human tissue or RNA was purchased (Biochain, San Leandro, CA; Invitrogen, Leek, The Netherlands; Clontech, Palo Alto, CA) or donated (Netherlands Brain Bank, Amsterdam, the Netherlands) and poly A+ RNA was prepared by the PolyATract method according to manufacturers instructions (Promega, USA). The poly 10 A+ RNA samples from 20 body tissues and 19 brain-regions from 4 individuals per tissue (two males/two females) were quantitated using OD260nm measurement or the RiboGreen fluorescent method (Molecular Probes, Oregon, USA) and 1ug of each RNA was reverse transcribed using random nonomeric and Superscript II reverse transcriptase according to manufacturers 15 instructions (Life Technologies). The cDNA prepared was diluted to produce up to 1,000 replicate 96-well plates using Biomek robotics (Beckman Coulter, High Wycombe, UK), so that each of the wells contained the cDNA produced from 1ng RNA for the appropriate tissue. The 96-well plates were stored at -80°C prior to use.

TaqMan PCR: This was performed following the procedure published by Sarau H.M. et al, 20 ("Identification, Molecular Cloning, Expression and Characterisation of a Cysteinyl Leukotriene Receptor", Molecular Pharmacology, 1999, 56, 657-663.) TaqMan quantitative PCR was conducted to measure either NOT-1 or NOT1a using replicate 96-well plates. A 20ul volume of a PCR master mix (containing 2.5ul TaqMan buffer, 6ul 25mM MgCl₂, 0.5ul of 10mM dATP, 0.5ul of 20mM dUTP, 0.5ul of 10mM dCTP, 0.5ul of 10mM dGTP, 0.25ul Uracil-N-glycosylase, 25 1ul of 10uM forward primer, 1ul of 10uM reverse primer, 0.5ul 5uM TaqMan probe, 0.125ul TaqGold [PE Biosystems], 6.625ul water) was added to each well using Biomek robotics (Beckman Coulter, High Wycombe, UK), and the plate capped using optical caps (PE Biosystems). The PCR reaction was carried out on an ABI7700 Sequence Detector (PE Biosystems) using the PCR parameters: 50°C for 2 minutes, 95°C for 10 minutes and 45 cycles 30 of 94°C for 15 seconds, 60°C for 1 minute, and the level of mRNA-derived cDNA in each sample was calculated from the TaqMan signal using plasmid/genomic DNA calibration standards included in each run. The level of genomic DNA contaminating the original RNA samples was shown to be negligible (<10 copies genomic DNA/ng RNA) by TaqMan measurement of genomic sequence for ten genes in replicate samples taken through the reverse transcription

procedure described with the omission of reverse transcriptase. Gene-specific reagents for NOT-1:

forward primer: 5'-CCGCCAGCAATAATTGACAA-3',

reverse primer: 5'-TTCCATTATCATTCCAGTTCCCTTG-3',

5 TaqMan probe: 5'-CACTTTACCTTCTAAGACCTCCTCCAGCA-3';
and for NOT1a:

forward primer: 5'-TCCTTCGATTAGCATACAGAATA-3',

reverse primer: 5'-CCCGTGTCTCTGTGACCAT-3',

TaqMan probe: 5'-TCTGCCTCTCCTGCATTGCTGCC-3'.

10

Results

The results are shown in Table 1. Analysis of expression of both NOT1 and NOT1a mRNA by TaqMan showed relatively widespread distribution. However, the expression levels found in adipose tissue were significantly higher than for those found in any other tissue. Levels of expression are scored from +++++ to -, with +++++ representing the highest expression levels. +/- indicates weakly detectable expression.

Table 1

		NOT1	NOT1a
20	Brain	++	+
	Pituitary	-	++
	Heart	+	+/-
	Lung	+	+/-
	Liver	+	+
25	Foetal Liver	+	+/-
	Kidney	+	+
	Skeletal Muscle	++	++
	Stomach	+	+
	Intestine	+	+
30	Spleen	+	+
	Lymphocytes	++	++
	Macrophage	-	-
	Adipose	+++++	+++++
	Pancreas	+	+
35	Prostate	++	+

Placenta	+	+
Cartilage	+	+
Bone	-	-
Bone Marrow	+/-	+/-

5

Example 2 - Analysis of NOT1 expression in 3T3 cells

Insulin and dexamethasone induced differentiation of 3T3-L1 cells is an established in vitro model for adipogenesis. Levels of NOT1 mRNA were quantified in this model. The 3T3-L1 fibroblast cell line was obtained from the American Type Culture Collection. Cells were 10 grown to confluence in Dulbeccos modified Eagles Medium containing 10% FCS. Differentiation was undertaken with in Dulbeccos modified Eagles Medium containing 10% FCS supplemented with 0.5mM isobutyl methyl xanthine, 0.25uM dexamethasone and insulin (5ug/ml) for 48 hours followed by Dulbeccos modified Eagles Medium containing 10% FCS supplemented with insulin (5ug/ml) for a further 48 hours. Cells were grown in Dulbeccos modified Eagles Medium 15 containing 10% FCS for the remainder of the culture period.

On each day of experimentation the cell media was removed by aspiration and the cell monolayer extracted with 1ml of Trizol. RNA was prepared according to the manufacturer's instructions. Quantification of mRNA transcripts was carried out using the Taqman 5' nuclease assay as previously described (Wang T & Brown MJ (1999) Anal. Biochem. 269 p198-201). 20 Total RNA was treated with DNaseI (Gibco BRL) and reverse transcribed using random hexamers (Stratagene) and Superscript II reverse transcriptase (Gibco BRL). Transcript cDNA levels were then measured using Taqman assay primers and fluorogenic probes as described in example 1. The results are shown in Table 2. In Table 2, T1 refers to day 1, T2 to day 2 etc. and the figures in the right hand column indicate relative levels of Not1 mRNA, the figure on day 1 25 being 100%.

Table 2

T1	100
T2	139
T3	57
T4	2.8
T5	3.7
T6	0.9
T7	3.9
T8	8.7
T9	0.6
T10	n.d.
T11	3.4
T12	8.5

The results show that NOT1 expression is downregulated upon differentiation of 3T3-L1 cells, an established in vitro model for adipogenesis. This finding is consistent with NOT1 having a
5 function in maintaining the undifferentiated pre-adipocyte state.

SEQUENCE INFORMATION

SEQ ID NO:1

GCTCGCGCACGGCTCGCGGTCCCTTTGCCTGTCAGCCGGCCTGTCCTGCTCCCTCCCTCGTGAGTGTCCGGG
 TTCCCTCGCCCAGCTCTCCCACCCCTACCGACCCGGCGCCGGCTCCAGAGGGAACTGCACTTCGGCAGAGTTGA
 5 ATGAATGAAGAGAGACGGGAGACTCCTAAGGAGGAGTTGGACAGGCTGGACTCCCCATTGCTTCTAAAAATCTTG
 GAAAATTTGTCCTTCATTGAATTACGACACTGTCCACCTTAATTCTCGAAAACGCCGTAACTCGGCTGAAGCCATG
 CCTTGTGTTAGCGCAGTATGGTCCCTCGCTCAAGGAGGCCAGCCCCGCTCTCAGAGCTACAGTACCAACTCTCGGG
 AGAATAACAGCTCCGATTCTTAACTCCAGAGTTGCAAGTTAGCATGGACCTCACCAACACTGAAATCACTGCCACCA
 CTTCTCTCCCCAGCTTCAGTACCTTATGGACAACACAGCACAGGCTACGACGTCAAGGCCACCTGCTTGTACCAAATG
 10 CCCCTGTCCGGACAGCAGTCCTCCATTAAGGTAGAAGACATTAGATGCACAACCTACCAGCAACACAGGCCACCTGCC
 CCAGTCTGAGGAGATGATGCCGACTCCGGGCGTTACTACAAGCCCTCCTGCCCGACGCCACCCCCGGCT
 TCCAGGTGCAGCACAGCCCATGTGGACGACCCGGATCTCTCCACAACCTCCACCAGAAACTACGTGGCCACTACGCAC
 ATGATCGAGCAGAGGAAACGCCAGTCTCCGCCTCTCCCTCTCCCTTAAGCAATGCCCGCTGGCACCCGGTGT
 TAGTTGCCAGATGCCCTCGACGGGCCCCCTGCACGTCCCCATGAACCCGGAGGCCGCCGGCAGCCACACGTGGTGGACG
 15 GGCAGACCTTCGCTGTGCCAACCCATTGCAAGCCCGGTCCATGGCTTCCCGGGCGTGCAGATGCCACCGTCT
 CAGCTGCTCGACACCGCAGGTGCCCTACCGCCGTGCGGGCTCCCCCTCCAACGAGGGCTGTGCGCTGTGTGGGGA
 CAACGCCGCTGCCAACACTACGGCGTGCACCTGTAGGGCTGCAAAGGCTTCTTAAGCAGTGCACAGTGC
 AAAATACTGTGTAGCAAATAAAACTGCCAGTGGACAAGCGTGCACAGGAAATCGCTGTAGTACTGCCGATTTCAG
 AAGTGCCTGGCTGTTGGATGGTCAAAGAAGTGGTTCGCACAGACAGTTAAAAGGCCGAGAGGTGGCTTGC
 20 ACCGAAGAGCCCACAGGAGCCCTCTCCCCCTCGCCCCCGGTGAGTCTGATCAGTGCCTCGTCAGGCCCATGTC
 CCAACCCGGCTATGACCAGCCTGGACTATTCCAGGTTCCAGGCAACCCCTGACTATCAAATGAGTGGAGATGACACCCAG
 CATATCCAGCAATTCTATGATCTCCTGACTGGCTCATGGAGATCATCCGGGCTGGGAGAGAAACATCCCTGGCTTCGC
 AGACCTGCCAACGCCGACCAAGACCTGCTTTTGAAATCAGCTTCTTAGAACTGTTGCTTGCATTAGCATA
 CCAACCCAGTGGAGGGTAAACTCATCTTGCAATGGGTGGCTTGACAGGTTGCAATGCTTGC
 25 TGGATTGATTCCATTGTAATTCTCTCCAATTGCAAGAATATGAAACATCGACATTCTGCTTCTCTGCATTGCTGC
 CCTGGCTATGGTACAGAGAGACACGGCTCAAGGAACCCAGAGAGTGGAAAGAACTGCAAACAGATTGTAATTGTC
 TCAAAGACCACGTGACTTTCAACAATGGGGGTTGAACCGCCCAATTATTGTCACACTGTTGGGAAAGCTCCAGAA
 CTTCGTACCTTGCACACAGGGCTACAGCGCATTCTACCTGAAATTGAAAGACTTGGTGC
 30 GAAAGGCATTGGCTCCGGGATCTGGATTTAGAACATGGACTACACACAATACAGTGGTATAAAACTTTTATTCT
 CAGTTAAAAATCAGTTGTTGTCAGAAGAAAGATTGCTATAAGGTATAATGGAAATGTTGGCATGCTGGTGT
 GCAGTTCAGACAAATGTAACACACACACACACAGAGACACATCTAAGGGACCCACAAGTA
 35 TTGCCCTTAACAAGACTCAAAGTTCTGCTGTAAGAAAGCTGTAATATATAGTAAA
 ACTAAATGTTGCGTGGGGCATGAGTTGAAGAAGGCAAGGCTGTAATTACCAATGCAGTTGGCTTTAAATTATTGTC
 TAAATATTACAAATTCTAAAGATAAGTGTGTTGCAAAAAAAAGAAAATAAATACATA
 ATTCTAGGTTGAAATGTTAGGCACCTGCTACTTCAGTAATGCTATATTATATAAATGTT
 GTCTGTTAGATTATAAGGTTAGGCTAAACATTCTCAATTGTAAGGTTAGGTGGGC
 40 ACACATCAGAAAATCCTGACAAAAGGGACACATAGTGTGTTGTAACACCGTCAA
 TACCGTTGATGTTGATAAAAAGAAAGTTATATCTGATTATTGTTGTC
 AAAGCTAAACAAACTTGCATGCAGCAG

CTTTTGACTGTTCCAGAGTGCCTATAATACATAACTCCCTGGAAATAACTGAGCACTTGAATTTCATGTCTAA
 AAATTGTCAGTTAATTATTATTATTTGTTGAGTAAGAATTAAATTGCATATTCTGTAGTATTTCATGTATATT
 TCTAGTATGGCACATGATATGAGTCACTGCCTTTCTATGGTGTATGACAGTTAGAGATGCTGATTTCCTGAT
 AAATTCTTCTTGAGAAAGACAATTAAATGTTACAACAATAAACCATGTAATGAAAAAAA

5

SEQ ID NO:2

MPCVQAQYGSPPQGASPQSYSYHSSGEYSSDFLTPEFVKFSMDLTNTEITATTSLPSFSTFMD
 NYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQMHNYQQHSHLPPQSEEMMPHSGSVYYKPSSPPTP
 10 TTPGFQVQHSPMWDDPGSLHNFHQNYYATTHMIEQRKTPVSRLSLFSFKQSPPGTPVSSCQMRFD
 GPLHVPMNPEPAGSHHVVDGQTFAVPNPIRKPMGFPGLQIGHASQLLDTQVSPSPSRGSPSNE
 GLCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCVDKRRRNRCQYCRFQKCLA
 VGMVKEVVRTDSLKGRRGLPKPKSPQEPPSPPVSLISALVRAHVDSNPAMTSLDYSRFQAN
 PDYQMSGDDTQHIQQFYDLLTGSMEIIRGWAEKIPGFADLPKADQDLLFESAFLFVLRLAYRS
 NPVEGKLIFCNGVVLHRLQCVRGFGEWIDSIVEFSSNLQNMNIDISAFSCIAALAMVTERHGLKE
 15 PKRVEELQNKIVNCLKDHTFNNNGLNRPNYLSKLLGKLPELRTLCTQGLQRIFYLKLEDLVPPP
 AIIIDKLFLDLPPF

SEQ ID NO:3

ATGCCTTGTGTTCAAGCGCAGTATGGTCCTCGCCTCAAGGAGCCAGCCCCGCTTCAGAGCTA
 20 CAGTTACCACTCTCGGGAGAAATACAGCTCCGATTCTTAACCTCAGAGTTGTCAAGTTAGCA
 TGGACCTCACCAACACTGAAATCACTGCCACCCTCTCTCCCAGCTTCAGTACCTTATGGAC
 AACTACACGACAGGCTACGACGTCAGGCCACCTTGCTTGTACCAAATGCCCTGTCCGGACAGCA
 GTCTCCATTAAGGTAGAAGACATTAGATGCACAACTACCAGAACACAGGCCACCTGCC
 AGTCTGAGGAGATGATGCCGACTCCGGTCGGTTACTACAAGCCCTCTCGCCCCCGACGCC
 25 ACCACCCGGCTTCAAGGTGCAGCACAGCCCCATGTGGACGACCCGGATCTCTCCACAACCT
 CCACCAAGAACTACGTGCCACTACGCACATGATCGAGCAGAGGAAACGCCAGTCTCCGCC
 CCTCTTCTCTTTAAGCAATGCCCTGGCACCCGGTGTCTAGTTGCCAGATGCGCTTCGAC
 GGGCCCTGCACGTCCCCATGAACCCGGAGCCGCCGGCAGCCACACGTGGTGGACGGCAGAC
 CTTCGCTGTGCCAACCCATTGCAAGCCCGTCCATGGCTTCCGGGCTGCAGATGCC
 30 ACGCGTCTCAGCTGCTCGACACCGCAGGTGCCCTCACCGCCGTCGCGGGCTCCCCCTCAACAGAG
 GGGCTGTGCCTGTGTGGGACAACGCGGCCCTGCCAACACTACGGCGTGCACCTGTGAGGG
 CTGCAAAGGCTTCTTAAGCGCACAGTCAAAATGCAAAATACGTGTGTTAGCAAATAAAA
 ACTGCCAGTGGACAAGCGTCGCCGGAATCGCTGTCACTGCCGATTTCAGAAGTGCCTGGCT
 GTTGGGATGGTCAAAGAAGTGGTTCGCACAGACAGTTAAAAGGCCGGAGAGGTGTTGCC
 35 GAAACCGAAGAGCCCACAGGAGCCCTCTCCCCCTCGCCCCGGTGAGTCTGATCAGTGCCTCG

TCAGGGCCATGTCGACTCCAACCGGCTATGACCAGCCTGGACTATTCCAGGTTCCAGGCGAAC
CCTGACTATCAAATGAGTGGAGATGACACCCAGCATATCCAGCAATTCTATGATCTCCTGACTGG
CTCCATGGAGATCATCCGGGCAGAGAAGATCCCTGGCTTCGAGACCTGCCAAAGCCG
ACCAAGACCTGCTTTGAATCAGCTTCTTAGAACTGTTGTCTCGATTAGCATACAGAATA
5 TGAACATCGACATTCTGCCTTCTCCTGCATTGCTGCCCTGGCTATGGTCACAGAGAGACACGGG
CTCAAGGAACCCAAGAGAGTGGAAAGAACTGCAAAACAAGATTGTAAATTGTCTCAAAGACCACGT
GACTTTCAACAATGGGGGTTGAACCGCCCCAATTATTGTCAAACGTGGGGAAAGCTCCCAG
AACTTCGTACCCCTTGACACAGGGCTACAGCGCATTCTACCTGAAATTGGAAGACTTGGTG
CCACCGCCAGCAATAATTGACAAACTTCTGGACACTTACCTTCTAA

10

SEQ ID NO:4

MPCVQAQYGSPPQGASPASQSYHSSGEYSSDFLTPEFVKFSMDLTNTEITATTSLPSFSTFMD
NYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQMHNYYQHSHLPPQSEEMMPHSGSVYYKPSSPPTP
TPPGFQVHQHSPMWDDPGSLHNFHQNYVATTHMIEQRKTPVSRLSFLSFQKQSPPGTPVSSCQMRFD
15 GPLHVPMNPEPAGSHHVVDGQTFAVPNPIRKPASMGFPGLQIGHASQLLDTQVSPSPSRGSPSNE
GLCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCVDKRRRNRCQYCRFQKCLA
VGMVKEVVRTDSLKGRRGLPSPKSPQEPSPSPVSLISALVRAHVDNSNPAMTSLDYSRFQAN
PDYQMSGDDTQHIQQFYDLLTGSMEIIRGWAEKIPGFADLPKADQDLLFESAFLELFVLRLAYRI.

Claims

1. The use of a compound selected from:
 - (a) a NOT1 or NOT1a polypeptide;
 - 5 (b) a compound which activates a NOT1 or NOT1a polypeptide; or
 - (c) a polynucleotide encoding a NOT1 or NOT1a polypeptide,
for the manufacture of a medicament for treating:
 - (i) obesity;
 - (ii) insulin resistance;
 - 10 (iii) type 2 diabetes;
 - (iv) impaired glucose tolerance;
 - (v) cachexia; or
 - (vi) liposarcoma.
- 15 2. The use according to claim 1 wherein the medicament is used to treat obesity.
3. The use according to claim 1 wherein the medicament is used in the treatment of insulin resistance.
- 20 4. The use according to claim 1 wherein the medicament comprises an isolated polypeptide which comprises a polypeptide having at least 95% identity to the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
- 25 5. The use according to claim 4 wherein the isolated polypeptide is the NOT1 polypeptide of SEQ ID NO:2 or the NOT1a polypeptide of SEQ ID NO:4.
6. The use according to claim 1 wherein the medicament comprises a compound which activates a NOT or NOT1a polypeptide.
- 30 7. The use according to claim 1 wherein the medicament comprises a polynucleotide encoding a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
- 35 8. The use according to claim 7 wherein the polynucleotide comprises a polynucleotide having at least 95% identity with the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.
9. The use according to claim 7 or 8 wherein the polynucleotide has the polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 01/01211

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	A61K38/17	A61P3/04	A61P3/10	A61P5/48	C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 04675 A (MAGES HANS WERNER ;KROCKZEK RICHARD (DE)) 3 March 1994 (1994-03-03)	
A	SALIN-NORDSTROM T ET AL: "FUNCTION OF HUMAN NOT (NURR1/NR4A2) SPLICE VARIANTS IN DEVELOPMENT AND PATHOLOGIES" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/02, 1999, page 1754 XP000949970 ISSN: 0190-5295	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *V* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the International search report
11 July 2001	27/07/2001
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Blanco Urgoiti, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 01/01211

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MARUYAMA K ET AL: "THE NGFI-B SUBFAMILY OF THE NUCLEAR RECEPTOR SUPERFAMILY (REVIEW)" INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,,GR, vol. 12, no. 6, 23 March 1998 (1998-03-23), pages 1237-1243, XP000946431 ISSN: 1019-6439 ---	
A	ISHIHARA NORIKO ET AL: "Signal transduction pathways leading to the NOR-1 gene induction in MCF-7 breast cancer cells." FASEB JOURNAL, vol. 11, no. 9, 1997, page A1047 XP002171751 17th International Congress of Biochemistry and Molecular Biology in conjunction with the Annual Meeting of the American Society for Biochemistry and Molecular Biology; San Francisco, California, USA; August 24-29, 1997 ISSN: 0892-6638 ---	
A	MAMOUNAS M ET AL: "ANALYSIS OF THE GENES INVOLVED IN THE INSULIN TRANSMEMBRANE MITOGENIC SIGNAL IN CHINESE HAMSTER OVARY CELLS CHO-K1 UTILIZING INSULIN-INDEPENDENT MUTANTS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 88, no. 9, 1991, pages 3530-3534, XP002171752 1991 ISSN: 0027-8424 ---	
A	WO 98 26063 A (MAIRA MARIO ;DROUIN JACQUES (CA); MONTREAL INST RECH CLINIQUES (CA) 18 June 1998 (1998-06-18) ---	
P,A	WO 00 77202 A (SMITHKLINE BEECHAM PLC) 21 December 2000 (2000-12-21) cited in the application ---	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 6

Claims 1 (partially) and 6 refer to the use of an agonist of the polypeptides without giving a true technical characterization. Moreover no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 01/01211

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9404675	A	03-03-1994	AU	4950393 A	15-03-1994
WO 9826063	A	18-06-1998	CA	2192754 A	12-06-1998
			AU	5470598 A	03-07-1998
WO 0077202	A	21-12-2000	NONE		